Covid19 Clinical Trial
Official title:
Antikörperseroprävalenz Und Hintergrundinfektionsrate Von SARS-CoV-2 in Einem österreichischen Schlüsselkollektiv an Arbeitnehmer*Innen
Context: On March 11, the World Health Organization (WHO) announced the current corona virus
disease 2019 (COVID-19) outbreak as a pandemic. The first laboratory-confirmed case of
COVID-19 in Austria was announced on February 27, 2020. Since then, the incidence of
infection follows a gradual increase. Measurements taken by the Austrian government include
travel restrictions, closing of national borders, social distancing, a mandatory use of
facemasks in public, and closing of stores and restaurants. The underlying aim of those
imposed restrictions is to contain the viral transmission and to slow spreading of the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Objectives: The aims of this study are to determine i) how many employees in Austrian trauma
hospitals and rehabilitation facilities have virus specific IgG and IgM antibodies against
SARS-CoV-2, ii) how many are active virus carriers (symptomatic and asymptomatic), iii) how
many employees are in their incubation period during the study period, and iv) to calculate
the SARS-CoV-2 prevalence together with a specific occupation associated infection risk
within the different specifications of health care workers.
Study Design: Open uncontrolled observational cross-sectional study.
Setting/Participants: A total of 4000 employees in 11 Austrian trauma hospitals and
rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA) will
be invited to participate in the study.
Study Interventions and Measures: An antibody test for SARS-CoV-2 specific IgG and IgM
antibodies, and a RT-PCR test based on oropharyngeal swab samples, as well as
laboratory-based antibody tests using ELISA, will be implemented to ensure protection and
preservation of health in hospital staff and are not part of the study. The tests will be
conducted twice, with approximately two weeks in between testing. The results of the tests
will be used for statistical analysis in this study together with a questionnaire including
questions related to personal health, traveling activities, living situation, as well as
inquiries of symptoms and comorbidities.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |